Evidence map›Paper›PMID 31945055›Full record

SynthesisPLoS neglected tropical diseases2020

Systematic review of the effectiveness of selected drugs for preventive chemotherapy for Taenia solium taeniasis.

Michelle M Haby, Leopoldo A Sosa Leon, Ana Luciañez, Ruben Santiago Nicholls, Ludovic Reveiz, Meritxell Donadeu

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Eliminating morbidity caused by neglected tropical diseases by 2030.Revista panamericana de salud publica = Pan American journal of public health · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Drug repurposing applied: Activity of the anti-malarial mefloquine against Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2020
    Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Michelle M HabyDepartment of Chemical and Biological Sciences, University of Sonora, Hermosillo, Sonora, Mexico.ORCID 0000-0001-6203-9195
Leopoldo A Sosa LeonIndependent consultant, Hermosillo, Sonora, Mexico.
Ana LuciañezNeglected Infectious Diseases, Communicable Diseases and Environmental Determinants of Health, Pan American Health Organization/World Health Organization, Washington DC, United States of America.
Ruben Santiago NichollsNeglected Infectious Diseases, Communicable Diseases and Environmental Determinants of Health, Pan American Health Organization/World Health Organization, Washington DC, United States of America.
Ludovic ReveizDepartment of Evidence and Intelligence for Action in Health, Pan American Health Organization/World Health Organization, Washington DC, United States of America.
Meritxell DonadeuFaculty of Veterinary and Agricultural Sciences, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-2444-914X
World Health Organization Regional Office for the Americas · USThe University of Melbourne · AU

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundPreventive chemotherapy is a useful tool for the control of Taenia solium taeniasis and cysticercosis. The aim of this systematic review is to assess the scientific evidence concerning the effectiveness and safety of different drugs in preventive chemotherapy for T. solium taeniasis in endemic populations.

methodsA systematic review was conducted of controlled and uncontrolled studies, assessing the efficacy and adverse effects (among other outcomes) of albendazole, niclosamide and/or praziquantel for preventive chemotherapy of T. solium taeniasis. A comprehensive search was conducted for published and unpublished studies. Two reviewers screened articles, completed the data extraction and assessment of risk of bias. A meta-analysis of cure rate and relative reduction in prevalence was performed. The protocol for this review was registered on the International prospective register of systematic reviews (PROSPERO), number CRD42018112533.

resultsWe identified 3555 records, of which we included 20 primary studies reported across 33 articles. Meta-analyses of drug and dose showed that a single dose of praziquantel 10mg/kg, albendazole 400mg per day for three consecutive days, or niclosamide 2g, resulted in better cure rates for T. solium taeniasis (99.5%, 96.4% and 84.3%, respectively) than praziquantel 5mg/kg or single dose albendazole 400mg (89.0% and 52.0%, respectively). These findings have a low certainty of evidence due to high risk of bias in individual studies and heterogeneity in combined estimates. In relation to side-effects, most studies reported either no or only mild and transient side-effects within the first three days following drug administration for all drugs and doses.

conclusionEvidence indicated that praziquantel 10mg/kg, niclosamide 2g, and triple dose albendazole 400mg were effective as taenicides and could be considered for use in mass drug administration programs for the control of T. solium taeniasis. Evidence was not found that any of these drugs caused severe side effects at the indicated doses, although the extent of the available evidence was limited.

Indexed as

AlbendazoleAnimalsAnticestodal AgentsChemopreventionCysticercosisHumansNiclosamidePraziquantelTaeniasisTaenia soliumAlbendazoleAnticestodal AgentsNiclosamidePraziquantel

Identifiers

PMID31945055
PMCPMC6964831
OpenAlexW2999935240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.